Peering into the pharmaceutical “pipeline”: Investigational drugs, clinical trials, and industry priorities
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In spite of a growing literature on pharmaceuticalization, little is known about the pharmaceutical industry’s investments in research and development (R&D). Information about the drugs being developed can provide important context for existing case studies detailing the expanding – and often problematic – role of pharmaceuticals in society. To access the pharmaceutical industry’s pipeline, we constructed a database of drugs for which pharmaceutical companies reported initiating clinical trials over a five-year period (July 2006-June 2011), capturing 2,477 different drugs in 4,182 clinical trials. Comparing drugs in the pipeline that target diseases in high-income and low-income countries, we found that the number of drugs for diseases prevalent in high-income countries was 3.46 times higher than drugs for diseases prevalent in low-income countries. We also found that the plurality of drugs in the pipeline were being developed to treat cancers (26.2%). Interpreting our findings through the lens of pharmaceuticalization, we illustrate how investigating the entire drug development pipeline provides important information about patterns of pharmaceuticalization that are invisible when only marketed drugs are considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147 · cited 1×
“For example, some scholars have documented the extent to which industry-funded research generates results from clinical trials that make the drugs look safer and more effective than do independent studies (Healy, 2004; Lexchin et al., 2003).”
BackgroundImpure Science: AIDS, Activism, and the Politics of Knowledge
(1997) · Nature Medicine · doi:10.1038/nm0297-242 · Cited by 1,666
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918 · cited 8×
“We included all DDPN entries that reported on drugs that were in Phase I-III clinical trials, and we excluded entries that were regulatory updates (e.g., the filing of FDA applications or country-specific market approvals).”
BackgroundInfluentialBiomedicalization: Technoscientific Transformations of Health, Illness, and U.S. Biomedicine
Clarke, A. E., Shim, J. K., Mamo, L., Fosket, J. R., & Fishman, J. R. (2003) · American Sociological Review · doi:10.1177/000312240306800201 · Cited by 560
Pharmaceuticalization of Society in Context: Theoretical, Empirical and Health Dimensions
Abraham, J. (2010) · Sociology · doi:10.1177/0038038510369368 · Cited by 480
Pharmaceutical research and development: what do we get for all that money?
Light, D. W., & Lexchin, J. R. (2012) · BMJ · doi:10.1136/bmj.e4348 · Cited by 258 · cited 2×
“In spite of the powerful imagery, there is much evidence to suggest that the number of investigational drugs is on the decline and those that make it to market offer few therapeutic breakthroughs for patients (Angell, 2004; Light & Lexchin, 2012; Light & Warburton, 2011).”
Background
Cited by
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Self-citationFive insights from the Global Burden of Disease Study 2019
Murray, C. J. L., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasi-Kangevari, M., Abd-Allah, F., Abdollahi, M., Abedi, P., Abedi, A., Abolhassani, H., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31404-5 · Cited by 675
Self-citationAutism genetics: opportunities and challenges for clinical translation
Vorstman, J. A. S., Parr, J. R., Moreno-De-Luca, D., Anney, R. J. L., Nurnberger Jr, J. I., & Hallmayer, J. F. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.4 · Cited by 463
Likelihood of Null Effects of Large NHLBI Clinical Trials Has Increased over Time
Kaplan, R. M., & Irvin, V. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132382 · Cited by 356
“It has been argued that there have been few efficacious drugs in the pipeline[4,5].”
BackgroundBioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years
Stanton, D. N., Ganguli-Indra, G., Indra, A. K., & Karande, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020319 · Cited by 22
Metadata
- Authors
- Fisher, J. A., Cottingham, M. D., & Kalbaugh, C. A.
- Venue
- Social Science & Medicine
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 131
- Pages
- 322-330
- ISSN
- 0277-9536 (ISSN-L)
- OpenAlex
- W1975664878
- Cited by
- 63
- References
- 7
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peering into the pharmaceutical “pipeline”: Investigational drugs, clinical trials, and industry priorities. https://app.cochat.ai/papers/10.1016/j.socscimed.2014.08.023
- The paper
- Fisher, J. A., Cottingham, M. D., & Kalbaugh, C. A. (2015). Peering into the pharmaceutical “pipeline”: Investigational drugs, clinical trials, and industry priorities. Social Science & Medicine. https://doi.org/10.1016/j.socscimed.2014.08.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.